產(chǎn)品屬性：
產(chǎn)品名稱 | SRX3207 |
規(guī)格 | 5 mg、10 mg、25 mg、50 mg、100 mg |
貨號(hào) | EY-01Y13551 |
Cas No.: 2254693-15-5
別名: N/A
化學(xué)名: N/A
分子式: C29H29N7O3S
分子量: 555.65
溶解度: DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)
儲(chǔ)存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].SRX3207 has sufficient solubility in water (43 μmol/L)[1].SRX3207 (10 mg/kg, orally) increases antitumor immune response[1].[1]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020. [2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.
特別提醒公司產(chǎn)品僅供科研使用
